| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A phase I study assessing the safety and tolerability of allogeneic mesenchymal stem cell infusion in adults with cystic fibrosis
|
Roesch, Erica A.
|
|
|
22 |
3 |
p. 407-413
|
artikel
|
| 2 |
Bariatric surgery in a patient with cystic fibrosis and diabetes: A case report
|
Bruijn, N.R.A.
|
|
|
22 |
3 |
p. 577-579
|
artikel
|
| 3 |
Bone health outcomes in post-lung transplant patients with cystic fibrosis
|
Tran, Triet Vincent M.
|
|
|
22 |
3 |
p. 381-387
|
artikel
|
| 4 |
Clinical outcomes of adults and children with cystic fibrosis during the COVID-19 pandemic
|
Doumit, Michael
|
|
|
22 |
3 |
p. 581-586
|
artikel
|
| 5 |
Clinician perspectives on assessing for disordered eating and body image disturbance in adolescents and young adults with cystic fibrosis
|
Kass, Alexandra P.
|
|
|
22 |
3 |
p. 431-435
|
artikel
|
| 6 |
Contemporary cystic fibrosis incidence rates in Canada and the United States
|
Stephenson, Anne L.
|
|
|
22 |
3 |
p. 443-449
|
artikel
|
| 7 |
Cost burden among the CF population in the United States: A focus on debt, food insecurity, housing and health services
|
Seyoum, Semret
|
|
|
22 |
3 |
p. 471-477
|
artikel
|
| 8 |
Cystic fibrosis in a transformative era: Adapting to changing mental health needs
|
Landau, Eddie (Edwina) C.
|
|
|
22 |
3 |
p. 372-373
|
artikel
|
| 9 |
Cystic fibrosis prevalence in the United States and participation in the Cystic Fibrosis Foundation Patient Registry in 2020
|
Cromwell, Elizabeth A.
|
|
|
22 |
3 |
p. 436-442
|
artikel
|
| 10 |
Drug-drug interactions with CFTR modulator therapy in cystic fibrosis: Focus on Trikafta®/Kaftrio®
|
Purkayastha, Debanjali
|
|
|
22 |
3 |
p. 478-483
|
artikel
|
| 11 |
Early life growth trajectories in cystic fibrosis are associated with lung function at age six
|
Psoter, Kevin J.
|
|
|
22 |
3 |
p. 395-401
|
artikel
|
| 12 |
Editorial Board
|
|
|
|
22 |
3 |
p. ii
|
artikel
|
| 13 |
EFFECT OF ELEXACAFTOR/TEZACAFTOR/IVACAFTOR ON ANNUAL RATE OF LUNG FUNCTION DECLINE IN PEOPLE WITH CYSTIC FIBROSIS
|
Lee, Tim
|
|
|
22 |
3 |
p. 402-406
|
artikel
|
| 14 |
European survey of newborn bloodspot screening for CF: opportunity to address challenges and improve performance
|
Munck, Anne
|
|
|
22 |
3 |
p. 484-495
|
artikel
|
| 15 |
Factors associated with receiving CF care and use of telehealth in 2020 among persons with Cystic Fibrosis in the United States
|
Collaco, JM
|
|
|
22 |
3 |
p. 456-463
|
artikel
|
| 16 |
FDA-approved drug screening in patient-derived organoids demonstrates potential of drug repurposing for rare cystic fibrosis genotypes
|
de Poel, E.
|
|
|
22 |
3 |
p. 548-559
|
artikel
|
| 17 |
Growth trajectories in young children with cystic fibrosis: Where are we going?
|
Sanders, Don B.
|
|
|
22 |
3 |
p. 370-371
|
artikel
|
| 18 |
High rates of anxiety detected in mothers of children with inconclusive cystic fibrosis screening results
|
Ginsburg, Daniella K.
|
|
|
22 |
3 |
p. 420-426
|
artikel
|
| 19 |
Human papillomavirus prevalence, persistence and cervical dysplasia in females with cystic fibrosis
|
Rousset-Jablonski, C.
|
|
|
22 |
3 |
p. 505-514
|
artikel
|
| 20 |
Lived experiences of people with cystic fibrosis that were not eligible for elexacaftor-tezacaftor-ivacaftor (ETI): A qualitative study
|
Milo, Francesco
|
|
|
22 |
3 |
p. 414-419
|
artikel
|
| 21 |
Long-term tezacaftor/ivacaftor safety and efficacy in people with cystic fibrosis and an F508del-CFTR mutation: 96-week, open-label extension of the EXTEND trial
|
Flume, Patrick A.
|
|
|
22 |
3 |
p. 464-470
|
artikel
|
| 22 |
News
|
|
|
|
22 |
3 |
p. 365-366
|
artikel
|
| 23 |
Position paper: Models of post-transplant care for individuals with cystic fibrosis
|
McKone, Edward
|
|
|
22 |
3 |
p. 374-380
|
artikel
|
| 24 |
Regarding the article entitled “Effect of elexacaftor/tezacaftor/ivacaftor on annual rate of lung function decline in people with cystic fibrosis”
|
Hoo, Zhe Hui
|
|
|
22 |
3 |
p. 587
|
artikel
|
| 25 |
Rescue by elexacaftor-tezacaftor-ivacaftor of the G1244E cystic fibrosis mutation's stability and gating defects are dependent on cell background
|
Tomati, Valeria
|
|
|
22 |
3 |
p. 525-537
|
artikel
|
| 26 |
Steps Ahead: Optimising physical activity in adults with cystic fibrosis: A pilot randomised trial using wearable technology, goal setting and text message feedback
|
Curran, Máire
|
|
|
22 |
3 |
p. 570-576
|
artikel
|
| 27 |
Suicide attempts in adolescents with cystic fibrosis on Elexacaftor/Tezacaftor/Ivacaftor therapy
|
Arslan, Meliksah
|
|
|
22 |
3 |
p. 427-430
|
artikel
|
| 28 |
Targeted locus amplification reveals heterogeneity between and within CFTR genotypes and association with CFTR function in patient-derived intestinal organoids
|
Lefferts, J.W.
|
|
|
22 |
3 |
p. 538-547
|
artikel
|
| 29 |
The influence of exocrine pancreatic function on the exposure and pharmacokinetics of ivacaftor in people with cystic fibrosis
|
van der Meer, Renske
|
|
|
22 |
3 |
p. 564-569
|
artikel
|
| 30 |
The multi-faceted nature of 15 CFTR exonic variations: Impact on their functional classification and perspectives for therapy
|
Bergougnoux, A.
|
|
|
22 |
3 |
p. 515-524
|
artikel
|
| 31 |
The risk of colorectal cancer in individuals with mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) gene: An English population-based study
|
Birch, Rebecca J.
|
|
|
22 |
3 |
p. 499-504
|
artikel
|
| 32 |
The use of dornase alfa in patients with COVID-19
|
Ramachandram, Dinesh Sangarran
|
|
|
22 |
3 |
p. 580
|
artikel
|
| 33 |
The U UGA C sequence provides a favorable context to ELX-02 induced CFTR readthrough
|
Pranke, Iwona M.
|
|
|
22 |
3 |
p. 560-563
|
artikel
|
| 34 |
Trajectories of early growth and subsequent lung function in cystic fibrosis: An observational study using UK and Canadian registry data
|
Macdougall, Amy
|
|
|
22 |
3 |
p. 388-394
|
artikel
|
| 35 |
Treatment effects of Elexacaftor/Tezacaftor/Ivacaftor in people with CF carrying non-F508del mutations
|
Livnat, Galit
|
|
|
22 |
3 |
p. 450-455
|
artikel
|
| 36 |
Variability of the sweat test in children with Cystic Fibrosis previously CRMS/CFSPID: A retrospective monocenter experience
|
Terlizzi, Vito
|
|
|
22 |
3 |
p. 496-498
|
artikel
|
| 37 |
When triple therapy is not working: A reverse iceberg perspective
|
Castellani, Carlo
|
|
|
22 |
3 |
p. 367-369
|
artikel
|
Tijdschrift beschrijving